We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cost-Effectiveness Studies for Many Medicare Part D Medicines Are Scant, Say Researchers
Cost-Effectiveness Studies for Many Medicare Part D Medicines Are Scant, Say Researchers
A substantial proportion of Medicare Part D spending purchases drugs with absent or low-quality cost-effectiveness analyses, and this lack of analyses may cause problems for developing policies that address value in drug spending.